|Dr. Sanjay S. Shukla M.D., M.S.||Pres, CEO & Director||816.41k||N/A||1972|
|Ms. Jill M. Broadfoot||Chief Financial Officer||561.76k||N/A||1962|
|Ms. Nancy E. Denyes Krueger||Gen. Counsel & Corp. Sec.||537.59k||N/A||1968|
|Xiang-Lei Yang Ph.D.||Founder||N/A||N/A||N/A|
|Ms. Ashlee Dunston||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Peter Villiger||VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Danielle Campbell||VP of Human Resource||N/A||N/A||N/A|
|Dr. Ying J. Buechler Ph.D.||Exec. Director of Biologics Devel. & Manufacturing||N/A||N/A||N/A|
|Dr. Melissa A. Ashlock||Sr. Advisor||N/A||N/A||1958|
|Dr. David J. King||Scientific Consultant||N/A||N/A||1959|
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.